Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Antiviral Res. 2020 Feb 17;176:104749. doi: 10.1016/j.antiviral.2020.104749

Figure 7: In vivo antiviral activity of anisomycin against ZIKV.

Figure 7:

(A) Survival of AG129 mice after treatment with various doses of anisomycin administered for 10 days beginning 4 h after challenge with ZIKV (**p<0.01, *p<0.05). (B) Viral RNA obtained at 5dpi from serum of AG129 mice treated with various doses of anisomycin administered for 10 days beginning 4 h after challenge with ZIKV (**** p<0.0001, ** p<0.01, * p<0.05). (C) Weight change between 8 and 13 dpi, (D) time course weight change between 8 and 21 dpi and (E) disease signs of AG129 mice treated with various doses of anisomycin administered for 10 days beginning 4 h after challenge with ZIKV.